5 Best Vaccine Stocks To Buy Now

2. Pfizer Inc. (NYSE:PFE)

Number of Hedge Fund Holders: 70

Pfizer Inc. (NYSE:PFE) is a leading global diversified healthcare company that develops and manufactures prescription medicines, vaccines, and consumer health products. The company has a strong history of dividend growth, and the company’s dividend is well-covered by earnings. The company is a leader in the development of innovative new medicines, and its products are backed by a large and growing body of clinical data. Pfizer Inc. (NYSE:PFE) is one of the best vaccine stocks to buy now.

Shares of Pfizer Inc. (NYSE:PFE) have pulled back in 2022 and are presenting an attractive entry point for investors. As of October 28, the stock is trading at a PE multiple of 8x and is yielding 3.51%. The company has a strong cash position and has reported free cash flows of $28.4 billion.

On October 11, SVB Securities analyst David Risinger revised his price target on Pfizer Inc. (NYSE:PFE) to $48 from $53 and maintained a Market Perform rating on the shares. This October, Barclays analyst Carter Gould adjusted his price target on Pfizer Inc. (NYSE:PFE) to $44 from $50 and reiterated an Equal Weight rating on the shares.

At the end of Q2 2022, Pfizer Inc. (NYSE:PFE) was spotted on 70 hedge fund portfolios. These funds disclosed stakes of $2.80 billion in the company. As of June 30, AQR Capital Management is the top investor in Pfizer Inc. (NYSE:PFE) and has stakes worth $553.9 million in the company.

Here is what Diamond Hill Capital had to say about Pfizer Inc. (NYSE:PFE) in its third-quarter 2022 investor letter:

“Also among our bottom contributors were health care products manufacturer Abbott Labs, global pharmaceutical company Pfizer Inc. (NYSE:PFE), media and technology giant Alphabet, and insurance company American International Group (AIG). Although Pfizer continues to report strong performance of its core drugs, sales of its COVID vaccine and treatment have likely peaked and sales are expected to decline going forward. We remain optimistic about the company long term as we believe management is taking the company in the right direction, focusing R&D, and making strategic acquisitions with profits generated from COVID vaccine sales.”